 |
|
Objective Assessment of Compliance With Psoriasis Treatment
Sameh Said Zaghloul, MBBCH, DDSc, MSc, MD;
Mark Jeremy David Goodfield, MD, FRCP
Arch Dermatol. 2004;140:408-414.
Objective To assess patient compliance with psoriasis treatment.
Design Open prospective study. Patients with psoriasis were examined and completed a brief medical and social history, a compliance assessment sheet, and the Dermatology Life Quality Index (DLQI). Patients were reexamined at 3 months, and their actual treatment use was assessed and compared with the expected use. Medication adherence was assessed by direct questioning.
Setting Dermatology outpatient clinic.
Patients Two hundred ninety-four patients fulfilled the inclusion criteria, and 201 completed the study.
Main Outcome Measure Adherence with topical and oral therapies, using objective and self-reporting methods and description of factors affecting compliance.
Results The overall mean ± SD medication adherence was 60.6% ± 33.0% (range, 0%-169%). The mean ± SD DLQI in the study was 17.4 ± 8.9 (range, 0-30). There was a highly significant negative correlation (r = –0.92) between these variables. Being female, married, employed, and not paying for prescriptions were characteristics associated with increased medication adherence and a lower DLQI. Medication adherence was greater for topical or combined therapy, for once-daily treatment, and for first-time use of treatment. Adverse effects reduced compliance. The major reasons for missing treatment were drinking alcohol, being fed up, forgetfulness, and being too busy. Patients with facial disease and with more extensive disease had lower medication adherence.
Conclusions A range of disease-related and social factors may affect compliance with psoriasis treatment. The inversely proportional relationship between DLQI and medication adherence reflects the interaction of physical and psychological factors, as well as perceived treatment failure.
From the Department of Dermatology, The General Infirmary at Leeds, England. The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Clinical Severity of Psoriasis in Last 20 Years of PUVA Study
Nijsten et al.
Arch Dermatol 2007;143:1113-1121.
ABSTRACT
| FULL TEXT
Balancing the Benefits and Risks of Drug Treatment: A Stated-Preference, Discrete Choice Experiment With Patients With Psoriasis
Seston et al.
Arch Dermatol 2007;143:1175-1179.
ABSTRACT
| FULL TEXT
Poor Adherence to Treatments: A Fundamental Principle of Dermatology
Ali et al.
Arch Dermatol 2007;143:912-915.
FULL TEXT
|
